StrideBio Revenue and Competitors

Location

$97.2M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • StrideBio's estimated annual revenue is currently $2M per year.(i)
  • StrideBio's estimated revenue per employee is $77,500
  • StrideBio's total funding is $97.2M.

Employee Data

  • StrideBio has 26 Employees.(i)
  • StrideBio grew their employee count by -82% last year.

StrideBio's People

NameTitleEmail/Phone
1
President and CEOReveal Email/Phone
2
VP Strategy & OperationsReveal Email/Phone
3
VP Strategy & OperationsReveal Email/Phone
4
VP Patient Engagement & AdvocacyReveal Email/Phone
5
VP Human ResourcesReveal Email/Phone
6
Chief Operating OfficerReveal Email/Phone
7
Director Financial Planning and AnalysisReveal Email/Phone
8
Senior Director, LegalReveal Email/Phone
9
Senior Scientific Project ManagerReveal Email/Phone
10
Office ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.9M777%N/AN/A
#2
$6221.7M40140-4%N/AN/A
#3
$2M130%N/AN/A
#4
$0.8M5-55%N/AN/A
#5
$2.8M186%$11.1MN/A
#6
$1M13-41%N/AN/A
#7
$1.7M110%N/AN/A
#8
$0.6M40%N/AN/A
#9
$5.9M38-5%N/AN/A
#10
$6.8M447%N/AN/A
Add Company

What Is StrideBio?

StrideBio is a product-driven, fully integrated gene therapy company focused on creating and developing innovative genetic medicines with life-changing or curative potential for patients with devastating conditions, including monogenic rare disease and beyond. We leverage our proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies. Improved characteristics of StrideBioᅢᄁ¬ツᆲ¬トᄁs AAV vectors include evasion of pre-existing neutralizing antibodies, tissue targeting and de-targeting, enhanced potency, and manufacturability at scale. Combined with our gene construct design expertise and in-house manufacturing capabilities, StrideBio is positioned to generate best-in-class genetic medicines that allow more patients to benefit with maximum efficiency. StrideBio is based in a state-of-the-art 24,000-square-foot facility in Research Triangle Park, N.C, which houses our offices, research labs and in-house AAV manufacturing facilities.

keywords:N/A

$97.2M

Total Funding

26

Number of Employees

$2M

Revenue (est)

-82%

Employee Growth %

N/A

Valuation

N/A

Accelerator

StrideBio News

2021-03-16 - StrideBio Closes $81.5M Series B Financing

StrideBio, Inc., a Research Triangle Park, N.C.-based developer of novel engineered adeno-associated virus (AAV) based gene therapies, closed a $81.5m Series B funding round. The round was co-led by Northpond Ventures and Novo Holdings A/S and included new investors Pontifax, Octagon Capital, S ...

2021-03-16 - StrideBio Announces Closing of $81.5M Series B Financing

RESEARCH TRIANGLE PARK, N.C., March 16, 2021 /PRNewswire/ -- StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the closing of an oversubscribed Series B funding round, which raised $81.5 million. The financing was co-led ...

2021-03-16 - StrideBio Announces Closing of $81.5M Series B Financing

RESEARCH TRIANGLE PARK, N.C., March 16, 2021 /PRNewswire/ -- StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the closing of an oversubscribed Series B funding round, which raised $81.5 million. The financing was co-led b ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.7M2673%N/A
#2
$2.7M2613%N/A
#3
$5.3M2624%N/A
#4
$2.6M26-4%N/A
#5
$4M2618%N/A